MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer

NCT00072930 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

BIOLOGICAL: MEDI-522
BIOLOGICAL: Docetaxel + Prednisone* + Zoledronic Acid

Sponsor

MedImmune LLC